Pharmacokinetic and pharmacodynamic features of antiretroviral products-Reference-Cited by-同舟云学术

Pharmacokinetic and pharmacodynamic features of antiretroviral products

Published:2022-11-09 Issue:3 Volume:14 Page:7-23
ISSN:2077-9828
Container-title:HIV Infection and Immunosuppressive Disorders
language:
Short-container-title:VIČ-infekc. immunosupr.

Author:

Useinova A. N.¹^ORCID,Egorova E. A.¹^ORCID,Maryanenko S. P.¹^ORCID,Kaliberdenko V. B.¹,Koryanova K. N.²^ORCID,Grogoryan K. E.²^ORCID

Affiliation:

1. Institute «Medical Academy named S. I. Georgievsky» Crimean Federal University named V. I. Vernadsky

2. Pyatigorsk Medical and Pharmaceutical Institute

Abstract

Introduction. Since the appearance of the immune deficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) at the beginning of 1980s, humanity started to understand elementary processes, underlying biology of HIV that enabled to develop safe and efficient treatment methods. Currently HIV therapy includes combined treatment regimen that allows combined drug interaction.Objective. To study the features of pharmacokinetics and pharmacodynamics, and also drug interaction of specific product groups, affecting human immunodeficiency virus.Materials and methods. Analytical review is based on analysis of literary sources of scientific database (PubMed, Cochrane Library, Сyberleninka) that contains information about peculiarities of pharmacokinetic and pharmacodynamic antiretroviral products’ interaction (ARVP) when used by HIV-infected patients for the period 1995–2022. Results and discussion. The current study enabled to summarize the research results, devoted to the issue of combined ARVP use by HIV-infected patients, and also to identify variants of irrational ARVP combination, caused by increased risk of toxicity with their simultaneous application.Conclusion. Studying the characteristics of each medical product, used in HIV infection therapy, allows to choose optimal pharmacotherapy regimens, taking into account individual patient characteristics, and also to predict and prevent the risk of adverse reactions in the future.

Publisher

Baltic Medical Education Center

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Immunology

Reference73 articles.

1. Tang M.W., Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications // Drugs. 2012. Vol. 72, No. 9. e1–25. DOI: 10.2165/11633630-000000000-00000.

2. Vavilova V.A., Shekunova E.V., Jain (Korsakova) E.A., Balabanyan V.Yu., Ozerov A.A., Makarova M.N., Makarov V.G. Experimental study of toxic properties of VMU-2012-05 drug — original nonnucleeside inhibitor of HIV-1 reverse transcriptase. Pharmacy & Pharmacology, 2021, Vol. 9, No. 3, рр. 205–221 (In Russ.). DOI: 10.19163/2307-9266-2021-9-3-205-221.

3. Saag M.S., Benson C.A., Gandhi R.T., Hoy J.F., Landovitz R.J., Mugavero M.J., Sax P.E., Smith D.M., Thompson M.A., Buchbinder S.P., Del Rio C., Eron J.J.Jr., Fätkenheuer G., Günthard H.F., Molina J.M., Jacobsen D.M., Volberding P.A. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel // JAMA. 2018. Vol. 320, No. 4. Р. 379–396. DOI: 10.1001/jama.2018.8431.

4. Pokrovsky V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Ermak T.N., Kanestri V.G., Shahgildyan V.I., Kozyrina N.V., Buravtsova V.V., Narsia R.S., Pokrovskaya A.V., Efremova O.S., Konnov V.V., Kuimova A.G., Popov A.A. Khokhlova H.E. National Guidelines for the Dispensary Surveillance and Treatment of HIV-infection. Clinical Protocol. Epidemiology and infectious diseases. Topical issues, 2016, Vol. 6 (Appendix), 120 р. (In Russ.).

5. Lukhwareni A., Gededzha M.P., Amponsah-Dacosta E., Blackard J.T., Burnett R.J., Selabe S.G., Kyaw T., Mphahlele M.J. Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans // Viruses. 2020. Vol. 12, No. 6. Р. 634. DOI: 10.3390/v12060634.